Frailty, Multimorbidity, and Polypharmacy

Kaitlin J. Mayne; Rebecca J. Sardell; Natalie Staplin; Parminder K. Judge; Doreen Zhu; Emily Sammons; David Z.I. Cherney; Alfred K. Cheung; Aldo Maggioni; Masaomi Nangaku; Xavier Rosselló; Katherine R. Tuttle; Katsuhito Ihara; Tomoko Iwata; Christoph Wanner; Jonathan Emberson; David Preiss; Martin Landray; Colin Baigent; Richard Haynes; William G. Herrington

doi:10.2215/cjn.0000000000000498

Related publications

Article2025

Multimorbidity, frailty and polypharmacy in European and Asian patients with atrial fibrillation: a comparison of two regional prospective observational registries

Davide Antonio Mei, Marco Proietti, Giulio Francesco Romiti, Tommaso Bucci, Bernadette Corica, Alena Shantsila, Hung‐Fat Tse, Giuseppe Boriani, Tze-Fan Chao, Professor Gregory Lip

Article2022

Impact of Multimorbidity and Polypharmacy on Clinical Outcomes of Elderly Chinese Patients with Atrial Fibrillation

Agnieszka Kotalczyk, Yutao Guo, Yutang Wang, Professor Gregory Lip

Article2020

Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey

Monika Kozieł, Stefan Simović, Nikola Pavlović, Aleksandar Kocijančić, Vilma Paparisto, Ljilja Musić, Elina Trendafilova, Anca Rodica Dan, Zumreta Kušljugić, Gheorghe‐Andrei Dan, Professor Gregory Lip, Tatjana Potpara

Article2020

Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial

Thomas Vanassche, Peter Verhamme, Darryl P. Leong, Deepak L. Bhatt, Olga Shestakovska, Aldo Maggioni, Keith A.A. Fox, Eva Muehlhofer, Stuart J. Connolly, Salim Yusuf, John W. Eikelboom, Jackie Bosch

Article2024

What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis

Konstantinos Prokopidis, Giuseppe Dario Testa, Nicola Veronese, Yannis Dionyssiotis, Joseph E. McLean, L. Walker, Rajiv Sankaranarayanan